Product Pipeline

HP163 as oral treatment of viral infection
  • HP163 is ready for IND enabling pre-clinical development 
  • In-vivo studies in models of Zika-virus infection show single agent efficacy of HP163, blocking viral replication and inhibiting microencephaly
  • AhR inhibitors show in-vitro efficacy against Dengue virus infection
  • Efficacy against Covid-19 is being tested
  • HP163 is protected by composition of matter patents.
Discovery of novel AhR inhibitors for treatment of cancer and viral infections
  • Hercules is engaged in the discovery of further novel AhR inhibitors for treatment of solid tumors and of viral infections